Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant.
We report the lst case of neuroleptic malignant syndrome occurring in a patient receiving desipramine, a tricyclic antidepressant, with no exposure to neuroleptics. Our case suggests that this syndrome may be caused by a central imbalance between norepinephrine and dopamine, and not by dopamine depletion alone.
Baca
L
L
Department of Medicine, Saint Joseph Hospital, Denver, CO 80218.
Martinelli
L
L
D001971:Bromocriptine / Q000627:therapeutic use; D003620:Dantrolene / Q000627:therapeutic use; D003891:Desipramine / Q000009:adverse effects*; D004298:Dopamine / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism
D001971:Bromocriptine; D003620:Dantrolene; D003891:Desipramine; D004298:Dopamine; D009638:Norepinephrine